5'-氨基-2,3'-联噻吩-4'-羧酸甲酯 | 444907-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 中文名称: 5'-氨基-2,3'-联噻吩-4'-羧酸甲酯
• 英文名称: methyl 5'-amino-2,3'-bithiophene-4'-carboxylate
• 英文别名: 5'-amino-[2,3']bithiophenyl-4'-carboxylic acid methyl ester；methyl 2-amino-4-thiophen-2-ylthiophene-3-carboxylate
• CAS: 444907-56-6
• 化学式: C₁₀H₉NO₂S₂
• mdl: MFCD02176908
• 分子量: 239.319
• InChiKey: YTPWWVXUJXQDMK-UHFFFAOYSA-N

物化性质

• 沸点：
  378.4±42.0 °C(Predicted)
• 密度：
  1.376±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5'-氨基-2,3'-联噻吩-4'-羧酸甲酯 在 盐酸 、 三氯氧磷 作用下， 以 1,4-二氧六环 为溶剂， 反应 38.0h， 生成 4-chloro-2,5-di(thiophen-2-yl)thieno[2,3-d]pyrimidine
  参考文献：
  名称：

  WO2007/102679

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 2-cyano-3-(thiophen-2-yl)but-2-enoate 在 哌啶 、 sulfur 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以31%的产率得到5'-氨基-2,3'-联噻吩-4'-羧酸甲酯
  参考文献：
  名称：

  Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents

  摘要：

  The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3). Therefore, FLT3 is regarded as a potential target for the treatment of AML A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors. All synthesized compounds were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60). Among these compounds, compound 17a, which possesses relatively short and simple substituents at the C-6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent. Compound 17a exhibited potent inhibition of FLT3-positive leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML. The data supports the further investigation of this class of compounds as potential anti-leukemic agents. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.08.001

文献信息

• Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors
  作者：Chun-Ho Park、Chulho Lee、Jee Sun Yang、Bo-Young Joe、Kwangwoo Chun、Hyuntae Kim、Hye Yun Kim、Jong Soon Kang、Jangik I. Lee、Myung-Hwa Kim、Gyoonhee Han

  DOI：10.1016/j.bmcl.2014.04.058

  日期：2014.6

  Inactivation of the NF-kappa B signaling pathway by inhibition of IKK beta is a well-known approach to treat inflammatory diseases such as rheumatoid arthritis and cancer. Thienopyrimidine-based analogues were designed through modification of the known IKKb inhibitor, SPC-839, and then biologically evaluated. The resulting analogues had good inhibitory activity against both nitric oxide and TNF-alpha, which are well-known inflammatory responses generated by activated NF-kappa B. However, no inhibitory activity against IKK beta was observed with these compounds. The thienopyrimidine-based analogues were subsequently screened for a target kinase, and FLT3, which is a potential target for acute myeloid leukemia (AML), was identified. Thienopyrimidine-based FLT3 inhibitors showed good inhibition profiles against FLT3 under 1 mu M. Overall, these compounds represent a promising family of inhibitors for future development of a treatment for AML. (C) 2014 Elsevier Ltd. All rights reserved.
• [EN] NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAUX DÉRIVÉS DE LA THIÉNOPYRIMIDINE OU LEURS SELS PHARMACOCOMPATIBLES, LEUR PROCÉDÉ DE PRÉPARATION, ET PRÉPARATIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：JE IL PHARMACEUTICAL CO LTD

  公开号：WO2007102679A1

  公开（公告）日：2007-09-13

  [EN] The present invention relates to a novel thienopyrimidine derivative having an excellent anti¬ inflammatory and anti-cancer activity, or a pharmaceutically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition comprising the same. The compound according to the present invention strongly inhibits IKB kinase-ß (IKK-ß) involved in the activation of a transcriptional factor, NF-?B, which is associated with inducing various immune and inflammatory diseases, whereby a composition comprising the compound is a useful therapeutic agent against inflammatory diseases, in particular, arthritis and cancer.
  [FR] L'invention porte sur un nouveau dérivé de la thiénopyrimidine présentant une excellente activité anti- inflammatoire et anti-cancéreuse ou ses dérivés pharmacocompatibles, sur son procédé de préparation, et sur des préparations pharmaceutiques les comprenant. Ce composé inhibe fortement la kinase IKB-ß (IKK-ß) impliquée dans l'activation d'un facteur de transcription, le NF-?B, associé à l'induction de différentes maladies immunes et inflammatoires; les préparations le comprenant sont donc utiles contre les maladies inflammatoires dont en particulier l'arthrite et le cancer.
• Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents
  作者：Jee Sun Yang、Chun-Ho Park、Chulho Lee、Hwan Kim、Changmok Oh、Yejoo Choi、Jong Soon Kang、Jieun Yun、Jin-Hyun Jeong、Myung-Hwa Kim、Gyoonhee Han

  DOI：10.1016/j.ejmech.2014.08.001

  日期：2014.10

  The most common mutations in acute myeloid leukemia (AML) are those that cause the activation of FMS-like tyrosine kinase 3 (FLT3). Therefore, FLT3 is regarded as a potential target for the treatment of AML A novel series of thieno[2,3-d]pyrimidine-based analogs was designed and synthesized as FLT3 inhibitors. All synthesized compounds were assayed for the tyrosine kinase activity of FLT3 and growth inhibitory activity in four human leukemia cell lines (THP1, MV4-11, K562, and HL-60). Among these compounds, compound 17a, which possesses relatively short and simple substituents at the C-6 position of thieno[2,3-d]pyrimidine, emerged as the most promising anti-leukemic agent. Compound 17a exhibited potent inhibition of FLT3-positive leukemic cell growth and of the FLT3 D835Y kinase; such inhibition is required for the successful treatment of AML. The data supports the further investigation of this class of compounds as potential anti-leukemic agents. (C) 2014 Elsevier Masson SAS. All rights reserved.
• WO2007/102679
  申请人：——

  公开号：——

  公开（公告）日：——